其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Fluproquazone CAS Registry Number: 40507-23-1 氟丙喹宗

CAS Name: 4-(4-Fluorophenyl)-7-methyl-1-(1-methylethyl)-2(1H)-quinazolinone
Additional Names: 1-isopropyl-7-methyl-4-(p-fluorophenyl)-2(1H)-quinazolinoneTrademarks: Tormosyl
Percent Composit...
Literature References: Fluoro analog of proquazone, q.v. Prepn: G. E. Hardtmann et al., DE 2230393 (1973 to Sandoz), C.A. 78, 111363a (1973); G. E. Hardtmann, US 3937705 (1976 to Sandoz). Analgesic effect: U. Herrmann et al., Clin. Pharmacol. Ther. 27, 379 (1980); B. von Graffenried, E. Nuesch, Br. J. Clin. Pharmacol. 10, Suppl. 2, 225 (1980). Series of articles on pharmacology, metabolism, analysis, clinical studies, toxicology: Arzneim.-Forsch. 31, 871-940 (1981). Toxicity: G. Rüttimann et al., Arzneim.-Forsch. 31, 882 (1981).

DTAF CAS Registry Number: 51306-35-5 5-(4,6-二氯三嗪)氨基荧光素

CAS Name: 5-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one
Additional Names: 5-(4,6-dichlorotriazinyl)aminofluorescein
Percent Compos...
Literature References: Fluorochrome labelling agent related to fluorescein, q.v. Prepn: V. E. Barskii et al., Izv. Akad. Nauk Ser. Biol. 1968, 744, C.A. 70, 79127 (1969); and use as label: D. Blakeslee, M. G. Baines, J. Immunol. Methods 13, 305 (1976). Practical comparison with FITC, q.v., for labelling: S. P. D. Lalljie, P. Sandra, Chromatographia 40, 519 (1995). Use as label for carbohydrates and proteins: R. Schumann, D. Rentsch, Mar. Ecol. Prog. Ser. 163, 77 (1998); for poloxamers, q.v.: F. Ahmed et al., Langmuir 17, 537 (2001). Ultrasensitive chromatographic/fluorescent determn of amino acid herbicides: M. Molina, M. Silva, Electrophoresis 23, 1096 (2002).

Difloxacin CAS Registry Number: 98106-17-3 双氟沙星

CAS Name: 6-Fluoro-1-(4-fluorophenyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Percent Composition: C 63.15%, H 4.80%, F 9.51%, N 10.52%, O 12.02%
Literature References: Fluoroquinolone antibacterial structurally related to norfloxacin, q.v. Prepn: D. T. W. Chu, EP 131839; idem, US 4730000 (1985, 1988 both to Abbott); D. T. W. Chu et al., J. Med. Chem. 28, 1558 (1985); H. Narita et al., JP Kokai 85 237069 (1985 to Toyama). Antibacterial spectrum in vitro: J. M. Stamm et al., Antimicrob. Agents Chemother. 29, 193 (1986); in vivo: P. B. Fernandes et al., ibid. 201. Activity vs anaerobic bacteria: eidem, J. Antimicrob. Chemother. 18, 693 (1986). HPLC determn in biological fluids: G. R. Granneman, L. T. Sennello, J. Chromatogr. 413, 199 (1987). Pharmacokinetics in humans: G. R. Granneman et al., Antimicrob. Agents Chemother. 30, 689 (1986).

Prulifloxacin CAS Registry Number: 123447-62-1 普卢利沙星

CAS Name: 6-Fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acidTrademarks: Quisnon (Nippon Shinyaku); Sword (Me...
Literature References: Fluoroquinolone antibacterial; prodrug for active metabolite, ulifloxacin. Prepn: M. Kise et al., EP 315828; eidem, US 5086049 (1989, 1992 both to Nippon Shinyaku); J. Segawa et al., J. Med. Chem. 35, 4727 (1992). Comparative in vivo activity: M. Ozaki et al., Antimicrob. Agents Chemother. 35, 2496 (1991). Clinical pharmacokinetics: M. Nakashima et al., J. Clin. Pharmacol. 34, 930 (1994). Clinical comparison with ciprofloxacin in chronic bronchitis: C. Grassi et al., Respiration 69, 217 (2002). Review of pharmacology: M. G. Matera, Pulm. Pharmacol. Ther. 19, 20-29 (2006); of clinical development: M. Cazzola et al., ibid. 30-37.

Ibotenic Acid CAS Registry Number: 2552-55-8 鹅膏氨酸

CAS Name: a-Amino-2,3-dihydro-3-oxo-5-isoxazoleacetic acid
Additional Names: a-amino-3-hydroxy-5-isoxazoleacetic acid; amino-(3-hydroxy-5-isoxazolyl)acetic acid
Percent Composition: C 37.98%...
Literature References: Fly-killing and narcosis-potentiating amino acid structurally similar to kainic acid, q.v., extracted from poisonous mushroom species. Isoln from Amanita pantherina (DC.) Fr., and A. muscaria (L.) Fr., Agaricaceae: Takemoto et al., J. Pharm. Soc. Jpn. 84, 1233 (1964); Eugster et al., Tetrahedron Lett. 1965, 1813. Structure: Takemoto et al., J. Pharm. Soc. Jpn. 84, 1186, 1232 (1964). Syntheses: Gagneux et al., Tetrahedron Lett. 1965, 2081; Sirakawa et al., Chem. Pharm. Bull. 14, 89 (1966); Kishida et al., ibid. 14, 92 (1966); 15, 1025 (1967). Improved synthesis: Nakamura, ibid. 19, 46 (1971). Industrial pats: BE 665249 C.A. 65, 2266e (1966); Gagneux et al., US 3459862 (1965, 1969 both to Geigy); Kishida et al., JP 68 15975; JP 69 25780 (1968, 1969 both to Sankyo), C.A. 70, 77944p (1969); 72, 13054g (1970). Pharmacology: Theobald et al., Arzneim.-Forsch. 18, 311 (1968); Johnston et al., Biochem. Pharmacol. 17, 2488 (1968). Exhibits potent neuroexcitatory activity: eidem, Nature 248, 804 (1974). Chemistry review: Eugster, Fortschr. Chem. Org. Naturst. 27, 261-321 (1969); Catalfomo, Eugster, Bull. Narc. 22, 33-41 (1970). Excitatory and possible sedative actions on spinal neurons: D. R. Curtis et al., J. Physiol. 291, 19 (1979); in cerebral cortex: E. Puil, Can. J. Physiol. Pharmacol. 59, 1025 (1981). Use as experimental neurotoxic agent: A. Contestabile et al., Experientia 40, 524 (1984).

Raltitrexed CAS Registry Number: 112887-68-0 雷替曲塞

CAS Name: N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid
Additional Names: N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-...
Literature References: Folate-based inhibitor of thymidylate synthase; rapidly and extensively metabolized to its more potent polyglutamate derivatives. Prepn: L. R. Hughes, EP 239362 (1987 to ICI; Natl. Res. Dev.); idem, US 4992550 (1991 to ICI); P. R. Marsham et al., J. Med. Chem. 34, 1594 (1991). Pharmacokinetics: D. I. Jodrell et al., Cancer Chemother. Pharmacol. 28, 331 (1991). HPLC determn of metabolites in cultured cells: W. Gibson et al., Biochem. Pharmacol. 45, 863 (1993). Review of clinical toxicology: S. J. Clarke et al., Adv. Exp. Med. Biol. 338, 601-604 (1993); of mechanism of action: A. L. Jackman et al., ibid. 339, 265-276. Historical development, pharmacology, and clinical evaluation: S. J. Clarke et al., ibid. 277-287; A. L. Jackman et al., Eur. J. Cancer 31A, 1277-1282 (1995).

Ninopterin CAS Registry Number: 2179-16-0 (2S)-2-[[4-[1-(2-氨基-4-氧代-1H-蝶啶-6-基)乙基氨基]苯甲酰基]氨基]戊二酸

CAS Name: N-[4-[[1-(2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]-L-glutamic acid
Additional Names: 9-methylpteroylglutamic acid; 9-methylfolic acid
Trademarks: Bremfol
Perc...
Literature References: Folic acid analog. Prepn: Hultquist et al., J. Am. Chem. Soc. 71, 619 (1949); Hultquist, Smith, GB 667098 (1952 to Am. Cyanamid). Clinical study in neoplastic diseases: J. C. Wright et al., J. Natl. Med. Assoc. 43, 211 (1951). In vitro evaluation as folic acid antagonist: S. Waxman et al., Chemotherapy (Basel) 28, 402 (1982).

Diopterin CAS Registry Number: 6807-82-5 N-(N-(4-(((2-氨基-1,4-二氢-4-氧代-6-蝶啶基)甲基)氨基)苯甲酰基)-L-alpha-谷氨酰)-L-谷氨酸

CAS Name: N-[N-[4-[[(2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-a-glutamyl]-L-glutamic acid
Additional Names: pteroyl-a-glutamylglutamic acid; pteroyldiglutamic acid; PDGA Literature References: Folic acid analog. Synthesis: Mowat et al., J. Am. Chem. Soc. 70, 1096 (1948); Hutchings, and Geraci, US 2500825 and US 2501168 (both 1950 to Am. Cyanamid); Geraci, US 2766240 (1956 to Aries Labs.).

Methotrexate CAS Registry Number: 59-05-2 甲氨蝶呤

CAS Name: N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Additional Names: 4-amino-N10-methylpteroylglutamic acid; 4-amino-10-methylfolic acid; methylaminopterin; ...
Literature References: Folic acid antagonist. Prepn: D. R. Seeger et al., J. Am. Chem. Soc. 71, 1753 (1949); J. M. Smith, D. B. Cosulich, US 2512572 (1950 to American Cyanamid). Metabolism: M. V. Freeman, J. Pharmacol. Exp. Ther. 122, 154 (1958); E. S. Henderson et al., Cancer Res. 25, 1008, 1018 (1965). Toxicity data: H. R. Scherf et al., Arzneim.-Forsch. 20, 1467 (1970). Comprehensive description: A. R. Chamberlin et al., Anal. Profiles Drug Subs. 5, 283-306 (1976). Review of metabolism and pharmacokinetics: W. E. Evans, Appl. Pharmacokinet. 1980, 518-548; of clinical pharmacology and toxicity: J. R. Bertino, Cancer Chemother. 3, 359-375 (1981); J. Jolivet et al., N. Engl. J. Med. 309, 1094-1104 (1983). Symposium on clinical experience in rheumatoid arthritis: J. Rheumatol. 12, Suppl. 12, 1-44 (1985). Review of use in leukemia: O. G. Jonsson, B. A. Kamen, Cancer Invest. 9, 53-60 (1991). Clinical trials in Crohn's disease: B. G. Feagan et al., N. Engl. J. Med. 332, 292 (1995); idem et al., ibid. 342, 1627 (2000). CE determn in blood: C.-Y. Kuo et al., J. Chromatogr. A 1014, 93 (2003). Review of pulmonary toxicity: O. Lateef et al., Expert Opin. Drug Saf. 4, 723-730 (2005).

Durohydroquinone CAS Registry Number: 527-18-4 四甲基氢醌

CAS Name: 2,3,5,6-Tetramethyl-1,4-benzenediol
Additional Names: tetramethyl-p-hydroquinone; dihydroxydurene
Percent Composition: C 72.26%, H 8.49%, O 19.25%
Literature References: For prepn see refs under Duroquinone.